Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 23

Sort by

Sort Order Select

Journal Articles

CD30.CAR-Modified Epstein-Barr Virus-Specific T Cells (CD30.CAR EBVSTs) Provide a Safe and Effective Off-the-Shelf Therapy for Patients with CD30-Positive Lymphoma

Blood (2022) 140 (Supplement 1): 412–414.

https://doi.org/10.1182/blood-2022-160244

Published: 2022

Journal Articles

Long-term follow-up for the development of subsequent malignancies in patients treated with genetically modified IECs

Blood (2022) 140 (1): 16–24.

https://doi.org/10.1182/blood.2022015728

Published: 2022

Journal Articles

Donor-Derived Adoptive T-Cell Therapy Targeting Multiple Tumor Associated Antigens to Prevent Post-Transplant Relapse in Patients with ALL

Blood (2021) 138 (Supplement 1): 471.

https://doi.org/10.1182/blood-2021-149332

Published: 2021

Journal Articles

Safety and Efficacy of Off-the-Shelf CD30.CAR-Modified Epstein-Barr Virus-Specific T Cells in Patients with CD30-Positive Lymphoma

Blood (2021) 138 (Supplement 1): 1763.

https://doi.org/10.1182/blood-2021-153421

Published: 2021

Journal Articles

Early Signals of Anti-Tumor Efficacy and Safety with Autologous CD5.CAR T-Cells in Patients with Refractory/Relapsed T-Cell Lymphoma

Rayne H. Rouce, LaQuisa C. Hill, Tyler S. Smith, Lina Yang, Blakely Boriskie, Madhuwanti Srinivasan, Huimin Zhang, Silvana Perconti, Birju Mehta, Olga Dakhova, Bambi J. Grilley, Helen E. Heslop, Malcolm K. Brenner, Maksim Mamonkin

Blood (2021) 138 (Supplement 1): 654.

https://doi.org/10.1182/blood-2021-154142

Published: 2021

Journal Articles

A Bank of CD30.CAR-Modified, Epstein-Barr Virus-Specific T Cells That Lacks Host Reactivity and Resists Graft Rejection for Patients with CD30-Positive Lymphoma

David H. Quach, PhD, Haran R. Ganesh, BS, Sachin Thakkar, PhD, Luis Becerra-Dominguez, BS, Birju Mehta, MS, Silvana Perconti, MS, Eric Anderson, BS, Emily M. Hsieh, MD, Olga Dakhova, MD, Huimin Zhang, BS, Bambi J. Grilley, RPh, Malcolm K. Brenner, MD PhD, Helen E. Heslop, MD DSc, Carlos A. Ramos, MD, Rayne H. Rouce, MD, Natalia Lapteva, PhD, Cliona M. Rooney, PhD

Blood (2020) 136 (Supplement 1): 16.

https://doi.org/10.1182/blood-2020-141491

Published: 2020

Journal Articles

Safety and Anti-Tumor Activity of CD5 CAR T-Cells in Patients with Relapsed/Refractory T-Cell Malignancies

LaQuisa C. Hill, MD, Rayne H. Rouce, MD, Tyler S. Smith, Lina Yang, PhD, Madhuwanti Srinivasan, Huimin Zhang, BS, Silvana Perconti, Birju Mehta, MS, BS, Olga Dakhova, Josalind Randall, Bambi J. Grilley, RPh, Helen E. Heslop, MD DSc, Malcolm K. Brenner, MD PhD, Maksim Mamonkin, PhD

Blood (2019) 134 (Supplement_1): 199.

https://doi.org/10.1182/blood-2019-129559

Published: 2019

Journal Articles

Targeting Lymphomas Using Non-Engineered, Multi-Antigen Specific T Cells

George Carrum, MD, Premal Lulla, MBBS, Ifigeneia Tzannou, MD, Ayumi Watanabe, Manik Kuvalekar, Mrinalini Bilgi, Rammurti Kamble, MD, Carlos A. Ramos, MD, Rayne Rouce, MD, Bambi J. Grilley, RPh, Adrian P. Gee, PhD, Malcolm K. Brenner, MD PhD, Helen E. Heslop, MDDSc, Cliona M. Rooney, PhD, Juan F. Vera, MD, Ann M. Leen, PhD

Blood (2018) 132 (Supplement 1): 1685.

https://doi.org/10.1182/blood-2018-99-113140

Published: 2018

Journal Articles

CD30-Chimeric Antigen Receptor (CAR) T Cells for Therapy of Hodgkin Lymphoma (HL)

Carlos A. Ramos, MD, Mrinalini Bilgi, Claudia P. Gerken, Olga Dakhova, Zhuyong Mei, Bambi J. Grilley, RPh, Adrian P. Gee, PhD, Cliona M. Rooney, PhD, Gianpietro Dotti, MD, Barbara Savoldo, MD PhD, Helen E. Heslop, MDDSc, Malcolm K. Brenner, MD PhD

Blood (2018) 132 (Supplement 1): 680.

https://doi.org/10.1182/blood-2018-99-111202

Published: 2018

Journal Articles

Adoptive T-Cell Therapy for Acute Lymphoblastic Leukemia Targeting Multiple Tumor Associated Antigens

Swati Naik, MBBS, Premal Lulla, MBBS, Ifigeneia Tzannou, MD, Robert A. Krance, MD, George Carrum, MD, Rammurti Kamble, MD, Carlos A. Ramos, MD, Catherine Robertson, Manik Kuvalekar, Ayumi Watanabe, Bambi J. Grilley, RPh, Juan F. Vera, MD, Helen E. Heslop, MDDSc, Ann M. Leen, PhD

Blood (2018) 132 (Supplement 1): 2693.

https://doi.org/10.1182/blood-2018-99-115465

Published: 2018

Journal Articles

Safety and Efficacy of Multiantigen-Targeted T Cells for Multiple Myeloma

Premal Lulla, MBBS, Ifigeneia Tzannou, MD, George Carrum, MD, Carlos A. Ramos, MD, Rammurti Kamble, MD, Mrinalini Bilgi, Shivani Mukhi, Betty Chung, DO,MPH,MA, Ayumi Watanabe, Manik Kuvalekar, Adrian P. Gee, PhD, Bambi J. Grilley, RPh, Malcolm K. Brenner, MD PhD, Helen E. Heslop, MDDSc, Juan F. Vera, MD, Ann M. Leen, PhD

Blood (2018) 132 (Supplement 1): 1014.

https://doi.org/10.1182/blood-2018-99-113118

Published: 2018

Journal Articles

Adoptive Immunotherapy with Rapidly-Generated Multivirus-Specific T Cells Against AdV, EBV, CMV, HHV6 and BK after Allogeneic Hematopoietic Stem Cell Transplant

Blood (2017) 130 (Supplement 1): 4484.

https://doi.org/10.1182/blood.V130.Suppl_1.4484.4484

Published: 2017

Journal Articles

Safety and Efficacy of Adoptively Transferred Donor-Derived Tumor-Directed T Cells with Relapsed AML Post-Allogeneic HSCT

Premal Lulla, MBBS, Swati Naik, MBBS, Ifigeneia Tzannou, MD, Carlos A. Ramos, MD, Rammurti Kamble, MD, Catherine Robertson, Ayumi Watanabe, Manik Kuvalekar, Bambi J. Grilley, RPh, George Carrum, MD, Helen E. Heslop, MDDSc, Juan F. Vera, MD, Ann M. Leen, PhD

Blood (2017) 130 (Supplement 1): 164.

https://doi.org/10.1182/blood.V130.Suppl_1.164.164

Published: 2017

Journal Articles

Adoptively-Transferred EBV-Specific T Cells to Prevent or Treat EBV-Related Lymphoproliferative Disease in Allogeneic HSCT Recipients - a Single Center Experience Spanning 22 Years

Ifigeneia Tzannou, MD, Bilal Omer, MD, Anastasia Papadopoulou, PhD, Ulrike Gerdemann, MD, Colton Smith, PhD, Adrian P. Gee, PhD, Bambi J Grilley, Malcolm K. Brenner, MB, PhD FRCP, FRCPath, Catherine M. Bollard, MD, Ann M. Leen, PhD, Cliona M. Rooney, PhD, Helen E. Heslop, MD

Blood (2015) 126 (23): 1926.

https://doi.org/10.1182/blood.V126.23.1926.1926

Published: 2015

Journal Articles

Inducible caspase-9 suicide gene controls adverse effects from alloreplete T cells after haploidentical stem cell transplantation

Xiaoou Zhou, Gianpietro Dotti, Robert A. Krance, Caridad A. Martinez, Swati Naik, Rammurti T. Kamble, April G. Durett, Olga Dakhova, Barbara Savoldo, Antonio Di Stasi, David M. Spencer, Yu-Feng Lin, Hao Liu, Bambi J. Grilley, Adrian P. Gee, Cliona M. Rooney, Helen E. Heslop, Malcolm K. Brenner

Blood (2015) 125 (26): 4103–4113.

https://doi.org/10.1182/blood-2015-02-628354

Published: 2015

Includes: Supplemental data

Journal Articles

Long-term outcome after haploidentical stem cell transplant and infusion of T cells expressing the inducible caspase 9 safety transgene

Xiaoou Zhou, Antonio Di Stasi, Siok-Keen Tey, Robert A. Krance, Caridad Martinez, Kathryn S. Leung, April G. Durett, Meng-Fen Wu, Hao Liu, Ann M. Leen, Barbara Savoldo, Yu-Feng Lin, Bambi J. Grilley, Adrian P. Gee, David M. Spencer, Cliona M. Rooney, Helen E. Heslop, Malcolm K. Brenner, Gianpietro Dotti

Blood (2014) 123 (25): 3895–3905.

https://doi.org/10.1182/blood-2014-01-551671

Published: 2014

Includes: Supplemental data

Journal Articles

Clinical Responses In Patients Infused With T Lymphocytes Redirected To Target κ-Light Immunoglobulin Chain

Carlos A. Ramos, MD, Barbara Savoldo, MD, PhD, Enli Liu, MD, MS, Adrian P. Gee, PhD, Zhuyong Mei, MD, Bambi J. Grilley, RPh, Cliona M. Rooney, PhD, Helen E. Heslop, MD, Malcolm K. Brenner, MD, PhD, Gianpietro Dotti, MD

Blood (2013) 122 (21): 506.

https://doi.org/10.1182/blood.V122.21.506.506

Published: 2013

Journal Articles

Infusion Of Donor-Derived CD19-Redirected-Virus-Specific T Cells For B-Cell Malignancies Relapsed After Allogeneic Stem Cell Transplant: A Phase I Study

Blood (2013) 122 (21): 152.

https://doi.org/10.1182/blood.V122.21.152.152

Published: 2013

Journal Articles

Infusion of donor-derived CD19-redirected virus-specific T cells for B-cell malignancies relapsed after allogeneic stem cell transplant: a phase 1 study

Blood (2013) 122 (17): 2965–2973.

https://doi.org/10.1182/blood-2013-06-506741

Published: 2013

Journal Articles

Multicenter study of banked third-party virus-specific T cells to treat severe viral infections after hematopoietic stem cell transplantation

Ann M. Leen, Catherine M. Bollard, Adam M. Mendizabal, Elizabeth J. Shpall, Paul Szabolcs, Joseph H. Antin, Neena Kapoor, Sung-Yun Pai, Scott D. Rowley, Partow Kebriaei, Bimalangshu R. Dey, Bambi J. Grilley, Adrian P. Gee, Malcolm K. Brenner, Cliona M. Rooney, Helen E. Heslop

Blood (2013) 121 (26): 5113–5123.

https://doi.org/10.1182/blood-2013-02-486324

Published: 2013

Includes: Supplemental data

NARROW

CD30.CAR-Modified Epstein-Barr Virus-Specific T Cells (CD30.CAR EBVSTs) Provide a Safe and Effective Off-the-Shelf Therapy for Patients with CD30-Positive Lymphoma

Long-term follow-up for the development of subsequent malignancies in patients treated with genetically modified IECs

Donor-Derived Adoptive T-Cell Therapy Targeting Multiple Tumor Associated Antigens to Prevent Post-Transplant Relapse in Patients with ALL

Safety and Efficacy of Off-the-Shelf CD30.CAR-Modified Epstein-Barr Virus-Specific T Cells in Patients with CD30-Positive Lymphoma

Early Signals of Anti-Tumor Efficacy and Safety with Autologous CD5.CAR T-Cells in Patients with Refractory/Relapsed T-Cell Lymphoma

A Bank of CD30.CAR-Modified, Epstein-Barr Virus-Specific T Cells That Lacks Host Reactivity and Resists Graft Rejection for Patients with CD30-Positive Lymphoma

Safety and Anti-Tumor Activity of CD5 CAR T-Cells in Patients with Relapsed/Refractory T-Cell Malignancies

Targeting Lymphomas Using Non-Engineered, Multi-Antigen Specific T Cells

CD30-Chimeric Antigen Receptor (CAR) T Cells for Therapy of Hodgkin Lymphoma (HL)

Adoptive T-Cell Therapy for Acute Lymphoblastic Leukemia Targeting Multiple Tumor Associated Antigens

Safety and Efficacy of Multiantigen-Targeted T Cells for Multiple Myeloma

Adoptive Immunotherapy with Rapidly-Generated Multivirus-Specific T Cells Against AdV, EBV, CMV, HHV6 and BK after Allogeneic Hematopoietic Stem Cell Transplant

Safety and Efficacy of Adoptively Transferred Donor-Derived Tumor-Directed T Cells with Relapsed AML Post-Allogeneic HSCT

Adoptively-Transferred EBV-Specific T Cells to Prevent or Treat EBV-Related Lymphoproliferative Disease in Allogeneic HSCT Recipients - a Single Center Experience Spanning 22 Years

Inducible caspase-9 suicide gene controls adverse effects from alloreplete T cells after haploidentical stem cell transplantation

Long-term outcome after haploidentical stem cell transplant and infusion of T cells expressing the inducible caspase 9 safety transgene

Clinical Responses In Patients Infused With T Lymphocytes Redirected To Target κ-Light Immunoglobulin Chain

Infusion Of Donor-Derived CD19-Redirected-Virus-Specific T Cells For B-Cell Malignancies Relapsed After Allogeneic Stem Cell Transplant: A Phase I Study

Infusion of donor-derived CD19-redirected virus-specific T cells for B-cell malignancies relapsed after allogeneic stem cell transplant: a phase 1 study

Multicenter study of banked third-party virus-specific T cells to treat severe viral infections after hematopoietic stem cell transplantation

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only